Robert Driscoll
Stock Analyst at Wedbush
(2.16)
# 2,932
Out of 5,044 analysts
151
Total ratings
35.34%
Success rate
-1.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $16.86 | +125.39% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $10.21 | +76.30% | 7 | Oct 20, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $77 | $58.02 | +32.71% | 7 | Oct 17, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $12.50 | +116.00% | 1 | Jul 14, 2025 | |
| KURA Kura Oncology | Reiterates: Outperform | $36 | $10.26 | +250.88% | 10 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.53 | +161.44% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.56 | +284.62% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $12.50 | +36.00% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $9.59 | +25.13% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $7.04 | +354.55% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $32.18 | +61.59% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $15.24 | +83.73% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.82 | +318.85% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $20.29 | +47.86% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.75 | +566.22% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.69 | +368.14% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.45 | +658.62% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.23 | +207.33% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.85 | +65.61% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $27.81 | +166.09% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.78 | +111.64% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.23 | +469.11% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $3.26 | +145.40% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.61 | -13.23% | 4 | May 19, 2020 |
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $16.86
Upside: +125.39%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $10.21
Upside: +76.30%
Revolution Medicines
Oct 17, 2025
Reiterates: Outperform
Price Target: $77
Current: $58.02
Upside: +32.71%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $12.50
Upside: +116.00%
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $10.26
Upside: +250.88%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.53
Upside: +161.44%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.56
Upside: +284.62%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $12.50
Upside: +36.00%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $9.59
Upside: +25.13%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $7.04
Upside: +354.55%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $32.18
Upside: +61.59%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $15.24
Upside: +83.73%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.82
Upside: +318.85%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $20.29
Upside: +47.86%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.75
Upside: +566.22%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.69
Upside: +368.14%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.45
Upside: +658.62%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.23
Upside: +207.33%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $7.85
Upside: +65.61%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $27.81
Upside: +166.09%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.78
Upside: +111.64%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.23
Upside: +469.11%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $3.26
Upside: +145.40%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.61
Upside: -13.23%